The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Saved in:
| Title: | The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. |
|---|---|
| Authors: | Ochman AR; Melior Discovery, Inc., 860 Springdale Dr., Exton, PA 19341, USA., Lipinski CA, Handler JA, Reaume AG, Saporito MS |
| Source: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2012 Jul; Vol. 342 (1), pp. 23-32. Date of Electronic Publication: 2012 Mar 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
